Render Target: STATIC
Render Timestamp: 2025-01-22T05:00:39.660Z
Commit: da7e4f2f0d1aed1f1f8e20e4e2ecab8f33cbd595
XML generation date: 2024-08-01 15:24:13.803
Product last modified at: 2025-01-07T14:45:08.589Z
Cell Signaling Technology Logo

Basket Updated

0

Items added

1% for the planet logo
PDP - Template Name: Polyclonal Antibody
PDP - Template ID: *******59c6464

Phospho-CrkL (Tyr207) Antibody #3181

Filter:
  • WB
  • IP
  • IHC
Western Blotting Image 1: Phospho-CrkL (Tyr207) Antibody
Western blot analysis of extracts from K562 cells, untreated or calf intestinal phosphatase (CIP)-treated, using Phospho-CrkL (Tyr207) Antibody (upper) or CrkL Antibody #3182 (lower).

To Purchase # 3181

Cat. # Size Qty. Price Ships
3181S 100 µl
$357
3181L 300 µl
$841

Supporting Data

REACTIVITY H M R Mk
SENSITIVITY Endogenous
MW (kDa) 39
SOURCE Rabbit
Application Key:
  • WB-Western Blotting 
  • IP-Immunoprecipitation 
  • IHC-Immunohistochemistry 
Species Cross-Reactivity Key:
  • H-Human 
  • M-Mouse 
  • R-Rat 
  • Mk-Monkey 
  • Related Products

Product Information

Product Usage Information

Application Dilution
Western Blotting 1:1000
Immunoprecipitation 1:50
Immunohistochemistry (Paraffin) 1:200

Storage

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.

Protocol

Specificity / Sensitivity

Phospho-CrkL (Tyr207) Antibody detects endogenous levels of CrkL only when phosphorylated at tyrosine 207. The antibody cross-reacts with CrkII phosphorylated at tyrosine 221.

Species Reactivity:

Human, Mouse, Rat, Monkey

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic phosphopeptide corresponding to residues surrounding Tyr207 of human CrkL. Antibodies are purified by protein A and peptide affinity chromatography

Background

CrkL, a 39 kDa adaptor protein, has a key regulatory role in hematopoietic cells. CrkL has one SH2 and two SH3 domains, with 60% homology to CrkII (1). The amino-terminal SH3 domain of CrkL binds proteins, such as C3G, SOS, PI3K, c-Abl, and BCR/Abl. The SH2 domain of CrkL can bind to tyrosine-phosphorylated proteins, such as Cbl, HEF1, CAS, and paxillin (2,3). CrkL is involved in various signaling cascades initiated by different cytokines and growth factors. The biological outcomes of the Crk-activated signal transduction include the modulation of cell adhesion, cell migration, and immune cell responses (4). CrkL is a prominent substrate of the BCR/Abl oncoprotein in chronic myelogenous leukemia and binds to both BCR/Abl and c-Abl (5). CrkL is prominently and constitutively tyrosine phosphorylated in CML neutrophils and is not phosphorylated in normal neutrophils. Moreover, stimulation of normal neutrophils with cytokines and agonists does not induce tyrosine phosphorylation of this protein (6), indicating that it may be a useful target for therapeutic intervention or as a disease marker. Tyr207 in CrkL is the BCR/Abl phosphorylation site (7).

Pathways

Explore pathways related to this product.


For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
All other trademarks are the property of their respective owners. Visit our Trademark Information page.